<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0134)http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?f=templates&fn=document-frame.htm&2.0 -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META content="text/html; charset=iso-8859-1" http-equiv=Content-Type><LINK 
href="0205_i1_files/bmj.css" rel=stylesheet type=text/css>
<META content="MSHTML 5.00.2920.0" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE border=1 borderColorDark=#ffffff borderColorLight=#c2c2c2 cellPadding=0 
cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0205_i1_files/0205_i1.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE border=0 width="100%">
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular 
            disorders</SECTION></SPAN><IMG align=absMiddle border=0 height=10 
            src="0205_i1_files/spacer.gif" width=10><BR><SPAN class=localhead 
            id=localhead><TOPIC>Primary prevention</TOPIC><IMG align=absMiddle 
            border=0 height=10 src="0205_i1_files/spacer.gif" 
        width=10></SPAN></TD></TR>
        <TR>
          <TD align=right bgColor=#ffffff class=title-author height=30 
          id=title-author noWrap vAlign=top><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0205_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p=">Clinical 
            Evidence writers on primary prevention</A><IMG align=absMiddle 
            border=0 height=10 src="0205_i1_files/spacer.gif" 
        width=10></TD></TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensive 
      drugs</H1>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of drug 
            treatment in primary hypertension?</B></TD></TR></TBODY></TABLE><BR><A 
      name=I1>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Versus 
      placebo</H2>
      <TABLE border=0 cellPadding=0 cellSpacing=0 width="100%">
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Antihypertensive drugs versus 
        placebo</B></TD></TR></TBODY></TABLE></A>
      <TABLE border=0 cellPadding=0 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD><A name=I1-SUMSTATEMENT><B>
            <P align=justify style="MARGIN-LEFT: 3px">Many systematic reviews of 
            RCTs have found that drug treatment decreases the risk of fatal and 
            non-fatal stroke, cardiac events, and total mortality in specific 
            populations of people. The biggest benefit is seen in people with 
            highest baseline risk of cardiovascular 
        disease.</P></B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I1-BENEFITS><B>Benefits: </B></A></FONT>We found many systematic 
              reviews. One review (search date 1997, 17 RCTs with morbidity and 
              mortality outcomes, duration &gt;&nbsp;1 year, 37&nbsp;000 people) 
              found that antihypertensive drugs versus placebo produced variable 
              reductions of systolic/diastolic blood pressure that averaged around 
              12&#8211;16/5&#8211;10&nbsp;mm&nbsp;Hg. <A 
            href="#references">[122]</A> It found evidence of benefit in total 
              death rate, cardiovascular death rate, stroke, major coronary events, 
              and congestive cardiac failure, but the absolute results depended 
              on age and the severity of the hypertension (see below). The biggest 
              benefit was seen in those with the highest baseline risk. The trials 
              mainly compared placebo versus diuretics (usually thiazides with 
              the addition of amiloride or triamterene) and versus ß blockers 
              (usually atenolol or metoprolol) in a stepped care approach. <font color="#FF0000">One 
              systematic review (search date 1999, 8 RCTs, 15&nbsp;693 people) 
              found that, in people over 60 years old with systolic hypertension, 
              treatment of systolic pressures greater than 160&nbsp;mm&nbsp;Hg 
              decreased total mortality and fatal and non-fatal cardiovascular 
              events. Absolute benefits were greater in men than women, in people 
              aged over 70, and in those with prior cardiovascular events or wider 
              pulse pressure. The relative hazard rates associated with a 10&nbsp;mm&nbsp;Hg 
              higher initial systolic blood pressure were 1.26 (P&nbsp;=&nbsp;0.0001) 
              for total mortality, 1.22 (P&nbsp;=&nbsp;0.02) for stroke, but only 
              1.07 (P&nbsp;=&nbsp;0.37) for coronary events. Active treatment 
              reduced total mortality (RR 0.87, 95% CI 0.78 to 0.98, P&nbsp;=&nbsp;0.02).</font> 
              <A 
            href="#references">[123]</A> <B>Target diastolic blood pressure:</B> 
              We found one RCT (18&nbsp;790 people, mean age 62 years, diastolic 
              blood pressures between 100&#8211;115&nbsp;mm&nbsp;Hg), which aimed 
              to evaluate the effects on cardiovascular risk of target diastolic 
              blood pressures of 90, 85, and 80&nbsp;mm&nbsp;Hg. <A 
            href="#references">[124]</A> However, mean achieved diastolic blood 
              pressures were 85, 83, and 81&nbsp;mm&nbsp;Hg, which limited power 
              to detect differences among groups. There were no significant differences 
              in major cardiovascular events among the three groups.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I1-HARMS><B>Harms: </B></A></FONT><B>Mortality 
              and major morbidity:</B> One systematic review of RCTs comparing 
              diuretics and ß blockers versus placebo found no increase in non-cardiovascular 
              mortality in treated people. <A 
            href="#references">[122]</A> One systematic review (9 case control 
              and 3 cohort studies) found that long term diuretic use may be associated 
              with an increased risk of renal cell carcinoma (OR in case control 
              studies 1.55, 95% CI 1.4 to 1.7). <A 
            href="#references">[125]</A> Absolute risks cannot be calculated from 
              these studies, but renal cell carcinoma is rare, so the absolute 
              risk increase of any real effect would be correspondingly small. 
              Renal cell carcinoma can cause hypertension; this fact may have 
              confounded the results of these studies. <B>Quality of life and 
              tolerability:</B> One systematic review and several recent trials 
              found that quality of life was not adversely affected and may be 
              improved in those who remain on treatment. <A 
            href="#references">[126]</A> <A 
            href="#references">[127]</A> </P>
          </TD></TR></TBODY></TABLE>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I1-COMMENT><B>Comment: 
              </B></A></FONT>Trials included people who were healthier than the 
              general population, with lower rates of cardiovascular risk factors, 
              cardiovascular disease, and comorbidity. People with higher cardiovascular 
              risk can expect greater short term absolute risk reduction than 
              seen in the trials, whereas people with major competing risks such 
              as terminal cancer or end stage Alzheimer's disease can expect smaller 
              risk reduction. In the systematic review, <A 
            href="#references">[122]</A> five of the trials were in middle aged 
              adults with mild to moderate hypertension. Seven of the trials were 
              in people older than 60 years. On average, every 1000 person years 
              of treatment in older adults prevented five strokes (95% CI 2 to 
              8), three coronary events (95% CI 1 to 4), and four cardiovascular 
              deaths (95% CI 1 to 8). Drug treatment in middle aged adults prevented 
              one stroke (95% CI 0 to 2) for every 1000 person years of treatment 
              and did not significantly affect coronary events or mortality.</P>
          </TD></TR></TBODY></TABLE><BR><A name=references></A>
      <TABLE border=0 cellPadding=0 cellSpacing=0>
        <TBODY>
        <TR>
          <TD bgColor=#404040 width=90><IMG align=absMiddle border=0 height=2 
            src="" width=1></TD>
          <TD bgColor=#404040 vAlign=bottom width="100%"><IMG align=absMiddle 
            border=0 height=2 src="" width=1></TD></TR>
        <TR>
          <TD bgColor=#404040 class=key-message id=key-message 
            width=90><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE align=center cellPadding=2 width="100%">
        <TBODY>
        <TR><A class=reference id=reference name=REF122></a>
          <TD class=reference id=reference vAlign=top width=15>122. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Gueyffier 
            F, Froment A, Gouton M. New meta-analysis of treatment trials of 
            hypertension: improving the estimate of therapeutic benefit. <EM>J 
            Hum Hypertens</EM> 1996;10:1&#8211;8. Search date 1997; primary source 
            Medline.</TD></TR>
        <TR><A class=reference id=reference name=REF123></a>
          <TD class=reference id=reference vAlign=top width=15>123. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Staessen 
            JA, Gasowski J, Wang JG, et al. Risks of untreated and treated 
            isolated systolic hypertension in the elderly: meta-analysis of 
            outcome trials. <EM>Lancet</EM> 2000;355:865&#8211;872. Search date 1999; 
            primary sources other systematic reviews and reports from 
            collaborative trialists.</TD></TR>
        <TR><A class=reference id=reference name=REF124></a>
          <TD class=reference id=reference vAlign=top width=15>124. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Hansson L, 
            Zanchetti AZ, Carruthers SG, et al. Effects of intensive blood pressure 
            lowering and low-dose aspirin in patients with hypertension: principal 
            results of the hypertension optimal treatment (HOT) trial. <EM>Lancet</EM> 
            1998;351:1755&#8211;1762. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF125></a>
          <TD class=reference id=reference vAlign=top width=15>125. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Grossman E, 
            Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of 
            renal cell carcinoma? <EM>Am J Cardiol</EM> 1999;83:1090&#8211;1093. 
            Search dates 1966 to 1998; primary sources Medline.</TD></TR>
        <TR><A class=reference id=reference name=REF126></a>
          <TD class=reference id=reference vAlign=top width=15>126. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Beto JA, 
            Bansal VK. Quality of life in treatment of hypertension: a 
            meta-analysis of clinical trials. <EM>Am J Hypertens</EM> 
            1992;5:125&#8211;133. Search date 1990; primary sources Medline, 
        ERIC.</TD></TR>
        <TR><A class=reference id=reference name=REF127></a>
          <TD class=reference id=reference vAlign=top width=15>127. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Croog SH, 
            Levine S, Testa MA. The effects of antihypertensive therapy on 
            quality of life. <EM>N Engl J Med</EM> 1986;314:1657&#8211;1664. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=86230742");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD></TR></TBODY></TABLE>
      <TABLE border=0 width="100%">
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" border=0 
            src="../ce-bmj-small-banner%5B1%5D.gif" width="89" height="44"></TD>
        </TR>
        <TR>
          <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 
          2001</SPAN></TD>
          <TD align=right width="50%"><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=1106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing 
            Group</SPAN></A></TD></TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0205.PDF"; 
</SCRIPT>
      </TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT name=LPHitCount type=hidden value=0> 
</FORM></BODY></HTML>
